Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer
share
Excerpt
Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, has announced a strategic collaboration with Sanofi to grant the non-exclusive license to Scribe’s CRISPR genome editing technologies that can enable genetic modification of novel natural killer (NK) cell therapies for cancer.
Article Summary
The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies. Scribe’s suite of custom engineering genome editing, and delivery tools called CasX-Editors (XE), based on novel foundations such as the CasX enzyme, will support Sanofi’s expanding pipeline of NK cell therapeutics for oncology.
Under the terms of the agreement, Scribe will receive $25 million in upfront payment and be eligible to potentially receive more than $1 billion in payments based on development and commercial milestones, as well as tiered royalties on net future sales on any products that may result from this research agreement.
Global Head of Research and Chief Scientific Officer, Sanofi has said that this collaboration with Scribe complements their robust research efforts across the NK cell therapy spectrum and offers their scientists unique access to engineered CRISPR-based technologies as they strive to deliver off-the-shelf NK cell therapies and novel combination approaches that improve upon the first generation of cell therapies.
About Scribe Therapeutics
Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen CRISPR by Design™ platform for genetic medicine.
Comments
Leave A Comment
Leave a Reply
